A second, complementary approach exploits the tumor-specific upregulation of CAIX as a highly selective “address” to which to deliver CAIX-specific monoclonal antibodies, either alone or in combination with cytotoxic or radioactive warheads to elicit killing of hypoxic tumor cells. This evidence concerns the gene CA9 and neoplasm.